



MACQUARIE UNIVERSITY CANCER BIOBANK

MQCB00104A REPORT


14 OCTOBER 2022

CLINICAL SUMMARY

Sex: Male
Age: 73
Pre-operative radiotherapy: No

HISTOPATHOLOGY

Specimen type: Anterior Resection
Tumour site: Sigmoid
Tumour type: Adenocarcinoma NOS, high-grade
Tumour stage: pT3N2a Stage IIIB
Tumour details: Mismatch proficient – MLH1, PMS2, MSH2, MSH6 normal staining by IHC
BRAFV600E negative by IHC
CDX2 positive (3+, greater than 90% by IHC)





60 – 75% Tumour Content

NEXT GENERATION GENOME/TRANSCRIPTOME DATA

Provider: Australian Genome Research Facility - 150bp paired end
Data yield: Germline DNA: 596,873,379 paired end, 180.26 Gbp
Tumour DNA: 914,049,646 paired end, 276.04 Gbp
Tumour RNA: 48,830,254 paired end, 14.75 Gbp

Top pathogenic somatic mutations			
Gene	Alteration	Allele Frequency	Function
TP53	c.700T>C p.Y234H	36%	Loss
NF1	c.4069T>G p.F1357V	7.87%	Loss
APC	c.4037C>A, p.S1346*	12%	Loss
APC	c.847C>T, p.R283*	20%	Loss

FLOW CYTOMETRY TUMOUR DISSOCIATE ANALYSIS



Cell Type	(%) of subset
Viable cells	31.4
Viable>CD45-	49.2
Viable>CD45+	47.8
Viable>CD45+>B cells	6.3
Viable>CD45+>CD4+/Foxp3-	18.0
Viable>CD45+>Tregs+	13.3
Viable>CD45+>CD8+	15.4
Viable>CD45+>Monocytes/Macrophages	14.1